Clinical Trial Detail

NCT ID NCT02316834
Title POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements no
Sponsors M.D. Anderson Cancer Center, BioMarin Pharmaceutical
Indications

fallopian tube carcinoma

ovary serous adenocarcinoma

peritoneal carcinoma

Therapies

Talazoparib

Age Groups: adult

No variant requirements are available.